{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:04:59Z","timestamp":1785855899697,"version":"3.56.0"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ageing Research Reviews"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.arr.2021.101552","type":"journal-article","created":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T21:32:59Z","timestamp":1640295179000},"page":"101552","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Association of F2-isoprostane levels with Alzheimer\u2019s disease in observational studies: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"74","author":[{"given":"Kira","family":"Trares","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Ju","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Sch\u00f6ttker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arr.2021.101552_bib1","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1042\/EBC20190096","article-title":"Moving forward with isoprostanes, neuroprostanes and phytoprostanes: where are we now?","volume":"64","author":"Ahmed","year":"2020","journal-title":"Essays Biochem."},{"key":"10.1016\/j.arr.2021.101552_bib2","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1159\/000504711","article-title":"Longitudinal associations of body mass index, waist circumference, and waist-to-hip ratio with biomarkers of oxidative stress in older adults: results of a large cohort study","volume":"13","author":"Anusruti","year":"2020","journal-title":"Obes. Facts"},{"key":"10.1016\/j.arr.2021.101552_bib3","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2019-000933","article-title":"Factors associated with high oxidative stress in patients with type 2 diabetes: a meta-analysis of two cohort studies","volume":"8","author":"Anusruti","year":"2020","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1016\/j.arr.2021.101552_bib4","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1089\/ars.2007.1956","article-title":"F2-isoprostanes in human health and diseases: from molecular mechanisms to clinical implications","volume":"10","author":"Basu","year":"2008","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.arr.2021.101552_bib5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S1570-0232(03)00600-7","article-title":"Determination of isoprostanes in urine samples from Alzheimer patients using porous graphitic carbon liquid chromatography-tandem mass spectrometry","volume":"796","author":"Bohnstedt","year":"2003","journal-title":"J. Chromatogr. B, Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.arr.2021.101552_bib6","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.neurobiolaging.2005.12.011","article-title":"Determinants of platelet activation in Alzheimer\u2019s disease","volume":"28","author":"Ciabattoni","year":"2007","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.arr.2021.101552_bib7","first-page":"604","article-title":"Isoprostanes: new markers of oxidative stress in human diseases","volume":"29","author":"Cracowski","year":"2000","journal-title":"Presse Med."},{"key":"10.1016\/j.arr.2021.101552_bib8","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.biochi.2016.08.002","article-title":"The novelty of phytofurans, isofurans, dihomo-isofurans and neurofurans: discovery, synthesis and potential application","volume":"130","author":"Cuyamendous","year":"2016","journal-title":"Biochimie"},{"key":"10.1016\/j.arr.2021.101552_bib9","doi-asserted-by":"crossref","first-page":"179","DOI":"10.13075\/ijomeh.1896.00596","article-title":"Isoprostanes - a novel major group of oxidative stress markers","volume":"29","author":"Czerska","year":"2016","journal-title":"Int. J. Occup. Med. Environ. Health"},{"key":"10.1016\/j.arr.2021.101552_bib10","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1042\/BST20140164","article-title":"Hypercholesterolaemia-induced oxidative stress at the blood-brain barrier","volume":"42","author":"Dias","year":"2014","journal-title":"Biochem Soc. Trans."},{"key":"10.1016\/j.arr.2021.101552_bib11","doi-asserted-by":"crossref","first-page":"563","DOI":"10.3233\/JAD-122227","article-title":"Increase in cerebrospinal fluid F2-isoprostanes is related to cognitive decline in APOE \u03b54 carriers","volume":"36","author":"Duits","year":"2013","journal-title":"J. Alzheimer\u2019S. Dis."},{"key":"10.1016\/j.arr.2021.101552_bib12","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","article-title":"Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis","volume":"56","author":"Duval","year":"2000","journal-title":"Biometrics"},{"key":"10.1016\/j.arr.2021.101552_bib13","article-title":"Guidance for the scientific requirements for health claims related to antioxidants, oxidative damage and cardiovascular health: (Revision 1)","volume":"16","author":"EFSA Panel on Dietetic Products","year":"2018","journal-title":"EFSA J."},{"key":"10.1016\/j.arr.2021.101552_bib14","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.talanta.2018.03.002","article-title":"Reliable determination of new lipid peroxidation compounds as potential early Alzheimer Disease biomarkers","volume":"184","author":"Garc\u00eda-Blanco","year":"2018","journal-title":"Talanta"},{"key":"10.1016\/j.arr.2021.101552_bib15","unstructured":"Gordon, M., Lumley, T., 2020. forestplot: Advanced Forest Plot Using 'grid' Graphics."},{"key":"10.1016\/j.arr.2021.101552_bib16","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.toxlet.2020.04.006","article-title":"Urinary 8-isoprostane as a biomarker for oxidative stress. A systematic review and meta-analysis","volume":"328","author":"Graille","year":"2020","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.arr.2021.101552_bib17","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3102\/10769986006002107","article-title":"Distribution theory for glass\u2019s estimator of effect size and related estimators","volume":"6","author":"Hedges","year":"1981","journal-title":"J. Educ. Stat."},{"key":"10.1016\/j.arr.2021.101552_bib18","doi-asserted-by":"crossref","first-page":"6072","DOI":"10.1002\/sim.3427","article-title":"Meta-analysis of skewed data: combining results reported on log-transformed or raw scales","volume":"27","author":"Higgins","year":"2008","journal-title":"Stat. Med."},{"key":"10.1016\/j.arr.2021.101552_bib19","series-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021)","article-title":"Chapter 6: Choosing effect measures and computing estimates of effect.","author":"Higgins","year":"2021"},{"key":"10.1016\/j.arr.2021.101552_bib20","doi-asserted-by":"crossref","first-page":"10919","DOI":"10.1021\/acsomega.0c00661","article-title":"High-throughput and sensitive analysis of free and total 8-isoprostane in urine with isotope-dilution liquid chromatography-tandem mass spectrometry","volume":"5","author":"Holder","year":"2020","journal-title":"ACS Omega"},{"key":"10.1016\/j.arr.2021.101552_bib21","doi-asserted-by":"crossref","first-page":"519","DOI":"10.3892\/br.2016.630","article-title":"Role of oxidative stress in Alzheimer\u2019s disease","volume":"4","author":"Huang","year":"2016","journal-title":"Biomed. Rep."},{"key":"10.1016\/j.arr.2021.101552_bib22","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/j.neurobiolaging.2011.05.013","article-title":"Serial CSF sampling in Alzheimer\u2019s disease: specific versus non-specific markers","volume":"33","author":"Kester","year":"2012","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.arr.2021.101552_bib23","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.brainresbull.2004.04.016","article-title":"Increased urinary F(2)-isoprostanes levels in the patients with Alzheimer\u2019s disease","volume":"64","author":"Kim","year":"2004","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.arr.2021.101552_bib24","first-page":"908","article-title":"Geometric means and measures of dispersion","volume":"35","author":"Kirkwood","year":"1979","journal-title":"Biometrics"},{"key":"10.1016\/j.arr.2021.101552_bib25","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/rcm.4871","article-title":"Quantification of 15-F2t-isoprostane in human plasma and urine: results from enzyme-linked immunoassay and liquid chromatography\/tandem mass spectrometry cannot be compared","volume":"25","author":"Klawitter","year":"2011","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1016\/j.arr.2021.101552_bib26","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1016\/S0022-3565(24)36968-X","article-title":"Generation of the isoprostane 8-epi-prostaglandin F2alpha in vitro and in vivo via the cyclooxygenases","volume":"282","author":"Klein","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.arr.2021.101552_bib27","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/ene.13439","article-title":"Alzheimer\u2019s disease","volume":"25","author":"Lane","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.arr.2021.101552_bib28","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1001\/jamaneurol.2014.445","article-title":"Cross-sectional and longitudinal relationships between cerebrospinal fluid biomarkers and cognitive function in people without cognitive impairment from across the adult life span","volume":"71","author":"Li","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.arr.2021.101552_bib29","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.psyneuen.2016.11.031","article-title":"Oxidative stress, inflammation and treatment response in major depression","volume":"76","author":"Lindqvist","year":"2017","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.arr.2021.101552_bib30","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.envint.2018.12.009","article-title":"How stable is oxidative stress level? An observational study of intra- and inter-individual variability in urinary oxidative stress biomarkers of DNA, proteins, and lipids in healthy individuals","volume":"123","author":"Martinez-Moral","year":"2019","journal-title":"Environ. Int."},{"key":"10.1016\/j.arr.2021.101552_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/antiox10030414","article-title":"Common and novel markers for measuring inflammation and oxidative stress ex vivo in research and clinical practice\u2014which to use regarding disease outcomes?","volume":"10","author":"Menzel","year":"2021","journal-title":"Antioxidants"},{"key":"10.1016\/j.arr.2021.101552_bib32","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/572491","article-title":"Isoprostanes and neuroprostanes as biomarkers of oxidative stress in neurodegenerative diseases","volume":"2014","author":"Miller","year":"2014","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.arr.2021.101552_bib33","doi-asserted-by":"crossref","first-page":"5973","DOI":"10.1021\/cr200160h","article-title":"Isoprostane generation and function","volume":"111","author":"Milne","year":"2011","journal-title":"Chem. Rev."},{"key":"10.1016\/j.arr.2021.101552_bib34","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.bbalip.2014.10.007","article-title":"The isoprostanes--25 years later","volume":"1851","author":"Milne","year":"2015","journal-title":"Biochim Biophys. Acta"},{"key":"10.1016\/j.arr.2021.101552_bib35","first-page":"631","article-title":"Oxidative stress and human hypertension: vascular mechanisms, biomarkers, and novel therapies","volume":"31","author":"Montezano","year":"2015","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.arr.2021.101552_bib36","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1212\/WNL.52.5.1104","article-title":"Cerebrospinal fluid F2-isoprostanes are elevated in Huntington's disease","volume":"52","author":"Montine","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.arr.2021.101552_bib37","doi-asserted-by":"crossref","first-page":"510","DOI":"10.5858\/2001-125-0510-CFATAF","article-title":"Cerebrospinal fluid abeta42, tau, and f2-isoprostane concentrations in patients with Alzheimer disease, other dementias, and in age-matched controls","volume":"125","author":"Montine","year":"2001","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.arr.2021.101552_bib38","doi-asserted-by":"crossref","first-page":"9383","DOI":"10.1073\/pnas.87.23.9383","article-title":"A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism","volume":"87","author":"Morrow","year":"1990","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.arr.2021.101552_bib39","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1159\/000289224","article-title":"Inability of plasma and urine F2A-isoprostane levels to differentiate mild cognitive impairment from Alzheimer\u2019s disease","volume":"7","author":"Mufson","year":"2010","journal-title":"Neuro-Degener. Dis."},{"key":"10.1016\/j.arr.2021.101552_bib40","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.plipres.2010.10.002","article-title":"F2-isoprostane formation, measurement and interpretation: the role of exercise","volume":"50","author":"Nikolaidis","year":"2011","journal-title":"Prog. Lipid Res."},{"key":"10.1016\/j.arr.2021.101552_bib41","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-50837-2","article-title":"New screening approach for Alzheimer\u2019s disease risk assessment from urine lipid peroxidation compounds","volume":"9","author":"Pe\u00f1a-Bautista","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.arr.2021.101552_bib42","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1001\/jamaneurol.2014.1428","article-title":"Influence of lifestyle modifications on age-related free radical injury to brain","volume":"71","author":"Peskind","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.arr.2021.101552_bib43","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.trsl.2008.05.009","article-title":"Infrared spectroscopy: a reagent-free method to distinguish Alzheimer\u2019s disease patients from normal-aging subjects","volume":"152","author":"Peuchant","year":"2008","journal-title":"Transl. Res.: J. Lab. Clin. Med."},{"key":"10.1016\/j.arr.2021.101552_bib44","doi-asserted-by":"crossref","first-page":"9800","DOI":"10.1074\/jbc.270.17.9800","article-title":"Cylooxygenase-dependent formation of the isoprostane, 8-epi prostaglandin F2\u03b1(\u2217)","volume":"270","author":"Pratico","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.arr.2021.101552_bib45","doi-asserted-by":"crossref","first-page":"8919","DOI":"10.1074\/jbc.271.15.8919","article-title":"Generation of 8-Epiprostaglandin F by Human Monocytes: discriminate production by reactive oxygen species and prostaglandin endoperoxide synthase-2 (\u2217)","volume":"271","author":"Pratic\u00f3","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.arr.2021.101552_bib46","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1096\/fasebj.12.15.1777","article-title":"Increased F2-isoprostanes in Alzheimer\u2019s disease: evidence for enhanced lipid peroxidation in vivo","volume":"12","author":"Pratic\u00f2","year":"1998","journal-title":"FASEB J."},{"key":"10.1016\/j.arr.2021.101552_bib47","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1002\/1531-8249(200011)48:5<809::AID-ANA19>3.0.CO;2-9","article-title":"Increased 8,12-iso-iPF2alpha-VI in Alzheimer\u2019s disease: correlation of a noninvasive index of lipid peroxidation with disease severity","volume":"48","author":"Pratic\u00f2","year":"2000","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.arr.2021.101552_bib48","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S0090-6980(97)00184-6","article-title":"Nomenclature of isoprostanes: a proposal","volume":"54","author":"Rokach","year":"1997","journal-title":"Prostaglandins"},{"key":"10.1016\/j.arr.2021.101552_bib49","series-title":"Publication Bias in Meta-Analysis: Prevention, Assessment and Adjustments","author":"Rothstein","year":"2005"},{"key":"10.1016\/j.arr.2021.101552_bib50","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-015-0537-7","article-title":"Evidence for the free radical\/oxidative stress theory of ageing from the CHANCES consortium: a meta-analysis of individual participant data","volume":"13","author":"Sch\u00f6ttker","year":"2015","journal-title":"BMC Med"},{"key":"10.1016\/j.arr.2021.101552_bib51","doi-asserted-by":"crossref","DOI":"10.1249\/MSS.0000000000002731","article-title":"Relationship of physical activity at older age with biomarkers of oxidative stress: a large, population-based cohort study","author":"Sch\u00f6ttker","year":"2021","journal-title":"Med. Sci. Sports Exerc."},{"key":"10.1016\/j.arr.2021.101552_bib52","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S0140-6736(21)00364-0","article-title":"New global initiative to tackle Alzheimer's disease","volume":"397","author":"Siva","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.arr.2021.101552_bib53","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3233\/JAD-2009-1125","article-title":"Systemic tocopherols and F2-isoprostanes and the risk of Alzheimer\u2019s disease and dementia: a prospective population-based study","volume":"18","author":"Sundel\u00f6f","year":"2009","journal-title":"J. Alzheimer\u2019S. Dis."},{"key":"10.1016\/j.arr.2021.101552_bib54","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0090-6980(97)00005-1","article-title":"A nomenclature system for the isoprostanes","volume":"53","author":"Taber","year":"1997","journal-title":"Prostaglandins"},{"key":"10.1016\/j.arr.2021.101552_bib55","series-title":"R: A Language and Environment for Statistical Computing, 3.6.3 ed.","author":"Team, R.C","year":"2020"},{"key":"10.1016\/j.arr.2021.101552_bib56","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/alz.12081","article-title":"Associations of urinary 8-iso-prostaglandin F(2\u03b1) levels with all-cause dementia, Alzheimer\u2019s disease, and vascular dementia incidence: results from a prospective cohort study","volume":"16","author":"Trares","year":"2020","journal-title":"Alzheimer\u2019S. Dement."},{"key":"10.1016\/j.arr.2021.101552_bib57","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0361-9230(01)00450-6","article-title":"Sign of lipid peroxidation as measured in the urine of patients with probable Alzheimer\u2019s disease","volume":"54","author":"Tuppo","year":"2001","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.arr.2021.101552_bib58","series-title":"Biological, Diagnostic and Therapeutic Advances in Alzheimer\u2019s Disease: Non-Pharmacological Therapies for Alzheimer\u2019s Disease","first-page":"91","article-title":"Oxidative stress in Alzheimer\u2019s disease: molecular hallmarks of underlying vulnerability","author":"Uddin","year":"2019"},{"key":"10.1016\/j.arr.2021.101552_bib59","doi-asserted-by":"crossref","first-page":"717","DOI":"10.3233\/JAD-160393","article-title":"Normal vitamin levels and nutritional indices in Alzheimer\u2019s disease patients with mild cognitive impairment or dementia with normal body mass indexes","volume":"55","author":"Ulstein","year":"2017","journal-title":"J. Alzheimer\u2019S. Dis."},{"key":"10.1016\/j.arr.2021.101552_bib60","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.freeradbiomed.2015.03.004","article-title":"Reinterpreting the best biomarker of oxidative stress: the 8-iso-PGF2\u03b1\/PGF2\u03b1 ratio distinguishes chemical from enzymatic lipid peroxidation","volume":"83","author":"van \u2018t Erve","year":"2015","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.arr.2021.101552_bib61","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.redox.2017.03.024","article-title":"Classifying oxidative stress by F(2)-isoprostane levels across human diseases: a meta-analysis","volume":"12","author":"van \u2019t Erve","year":"2017","journal-title":"Redox Biol."},{"key":"10.1016\/j.arr.2021.101552_bib62","first-page":"277","article-title":"Plasma F2-isoprostane levels are increased in Alzheimer\u2019s disease: evidence of increased oxidative stress in vivo","volume":"2","author":"Waddington","year":"1999","journal-title":"Alzheimer\u2019S. Rep."},{"key":"10.1016\/j.arr.2021.101552_bib63","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.arr.2021.101552_bib64","unstructured":"Wells, G., Shea, B., O'Connell, D., Peterson, J., Welch, V., Losos, M., Tugwel, P., 2019. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses."},{"key":"10.1016\/j.arr.2021.101552_bib65","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/6435861","article-title":"Oxidant\/antioxidant imbalance in Alzheimer\u2019s disease: therapeutic and diagnostic prospects","volume":"2018","author":"Wojsiat","year":"2018","journal-title":"Oxid. Med. Cell. Longev."}],"container-title":["Ageing Research Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568163721002993?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568163721002993?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T19:00:23Z","timestamp":1761591623000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568163721002993"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":65,"alternative-id":["S1568163721002993"],"URL":"https:\/\/doi.org\/10.1016\/j.arr.2021.101552","relation":{},"ISSN":["1568-1637"],"issn-type":[{"value":"1568-1637","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of F2-isoprostane levels with Alzheimer\u2019s disease in observational studies: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Ageing Research Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arr.2021.101552","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101552"}}